Applied BioMath and Tusk Therapeutics NV have entered a co-development agreement to quantify and analyse the drug properties and select pre-clinical drug candidates within immuno-oncology.

Pursuant to the agreement, the two partners will work on developing quantitative system pharmacology (QSP) model for a Tusk Therapeutics’ target and antibody candidates using Applied BioMath’s mechanistic modelling platform.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The agreement allows the two partners to develop pre-clinical drug candidate selection.

Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

As part of the agreement, the two partners will jointly advance the clinical development of Mironid’s LoAc molecules.

See Also:

The agreement enables the partners to produce new therapies for ADPKD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Mironid and the University of Sheffield have entered a collaboration agreement to develop new therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD)."

ApoGen Biotechnologies has raised $7m in a series A financing round, which was led by Accelerator Corporation and co-led by AbbVie Biotech Ventures, Alexandria Ventures Investments, ARCH venture Partners, Eli Lilly and Company and Johnson & Johnson Innovation.

The company plans to invest the funds to develop novel drugs to target resistance to cancer therapy.

Achaogen plans for an underwritten public offering of 6.5 million shares of its common stock.

The company expects to raise $87.75m through the offering, which is expected to be completed by 19 December.

Latham & Watkins is acting as the legal advisor for the offering.

The company intends to invest the funds to advance the development, marketing and commercialisation of Plazomicin and fund a variety of capital preservation investments.

Enumeral Biomedical Holdings has raised $3.4m through the private placement of 6.8 million shares of warrants.

The company plans to use the funds for its ongoing operations and for general corporate purposes.